Report Summary
Eternity Insights can provide a deep dive research report highlighting the market and competitive in-telligence across the key segments of the market. The report also considers the impact of COVID-19 on the global Oncology Drugs market. The report considers 2018-2020 historic period, 2021 as base year, and 2022-2028 as forecast period. The report includes quantitative analysis of the market supported by the mar-ket drivers, challenges, and trends to accurately map the market scenario and competition.
Oncology Drugs market report is based on robust research methodology designed using blend of research ap-proaches developed using secondary/desk research and validated through the primary research and expert insights. Eternity Insights also uses paid data bases such as FACIVA, Hoovers, and other bench-marking and forecasting tools to provide accurate statistical analysis of supply and demand trends.
To learn more about this report
Key Research Highlights: Market Drivers
The Oncology Drugs market is estimated to expand at a considerable growth rate during the forecast period ow-ing to increasing prevalence of venous diseases and increasing new product approvals to cater this demand. Rise in the awareness about the diseases, increasing importance of early diagnosis, and growing spending on chronic diseases are poised to boost the market growth. Moreover, the key players in the market are investing in research and development of technologically advanced products leading to increased utilization of the Oncology Drugs products across developed and developing countries of the world.
Key Research Highlights: Market Restrains
Limited awareness about the diseases, high cost of products, low economical condition, and lack of favorable insurance systems restricts the adoption of Oncology Drugs products across developing regions of the globe. However, launch of new products with low cost and increasing efforts for market penetration in these regions can offer lucrative growth opportunities for the players in the Oncology Drugs market.
To learn more about this report
Key Research Highlights: Trends
Increasing research and development spending on Oncology Drugs development has been the leading industry trend of Oncology Drugs market
The leading players in the market are focused on developing products which are cost effective and high quality to tap the huge unaddressed opportunities in the developing regions. This can be wit-nessed from the increasing spending on research and development and growing number of new product approvals.
Global Oncology Drugs Market Size, 2018-2028 (USD MILLION)
To learn more about this report
Market Segmentation
Report Attributes |
Details |
The market size value in 2021 |
USD XX.XX Million |
CAGR (2021 - 2028) |
XX.XX % |
The Revenue forecast in 2028 |
USD XX.XX Million |
Base year for estimation |
2021 |
Historical data |
2018-2019 |
Forecast period |
2022-2028 |
Quantitative units |
- Revenue in USD Million
- CAGR from 2021 to 2028
|
Report coverage |
Revenue forecast, company ranking, competitive landscape, growth factors, and trends |
Segments covered |
By Type Outlook, Application Outlook, Regional Outlook |
By Drug Class Outlook |
Cytotoxic Drugs, Targeted Drugs, Hormonal Drugs, Others |
By Therapy Outlook |
Chemotherapy, Targeted Therapy, Immunotherapy |
Regional scope |
North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Country scope |
U.S., Canada, U.K., Germany, France, BENELUX, China, India, Japan, South Korea, Brazil, Saudi Arabia, UAE, Turkey |
Key companies profiled |
Novartis A.G,Laboratrio Cristlia,Medley Genomics,F. Hoffmann-La Roche Ltd,Icon Plc.,Sanofi S.A.,Laboratoires Pierre Fabre,Eurofarma Laboratrios S.A.,Ach Laboratrios Farmacuticos S.A.,Laboratorios IMA |
Customization Available |
Yes, the report can be tailored to meet your specific requirements. |
Key Market Players
- Novartis A.G
- Laboratrio Cristlia
- Medley Genomics
- F. Hoffmann-La Roche Ltd
- Icon Plc.
- Sanofi S.A.
- Laboratoires Pierre Fabre
- Eurofarma Laboratrios S.A.
- Ach Laboratrios Farmacuticos S.A.
- Laboratorios IMA
Oncology Drugs Market, By Drug Class
- Cytotoxic Drugs
- Alkylating Agents
- Antimetabolites
- Others
- Targeted Drugs
- Monoclonal Antibodies
- Others
- Hormonal Drugs
- Others
Oncology Drugs Market, By Therapy
- Chemotherapy
- Targeted Therapy
- Immunotherapy
Oncology Drugs Market, By Indication
- Lung Cancer
- Stomach Cancer
- Colorectal Cancer
- Breast Cancer
- Prostate Cancer
- Others
Oncology Drugs Market, By Dosage Form
- Solid
- Liquid
- Injectable
- Prefilled Syringes
- Others
Oncology Drugs Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others
Key Benefits To The Stake Holders
- Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
- Provision of market value (USD Billion) and volume (Tons) data for each segment and sub-segment
- Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
- Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
- Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
- Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
- The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
Table Of Contents
Table of Contents
Global ONCOLOGY DRUGS Market by Manufacturers, Regions, Type and Application, Forecast to 2026
1 Report Overview
1.1 Definition and Specification
1.2 Report Overview
1.2.1 Manufacturers Overview
1.2.2 Regions Overview
1.2.3 Type Overview
1.2.4 Application Overview
1.3 Industrial Chain
1.3.1 ONCOLOGY DRUGS Overall Industrial Chain
1.3.2 Upstream
1.3.3 Downstream
1.4 Industry Situation
1.4.1 Industrial Policy
1.4.2 Product Preference
1.4.3 Economic/Political Environment
1.5 SWOT Analysis
2 Market Assessment by Type
2.1 Oral Therapy Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
2.2 Injectable Therapy Sales (K Units), Revenue (M USD) and Growth Rate 2014-2020
3 Asia Pacific ONCOLOGY DRUGS Market Assessment by Type
3.1 Asia Pacific Market Performance (Sales, Revenue)
3.2 Key Players in Asia Pacific
4 North America ONCOLOGY DRUGS Market Assessment by Type
4.1 North America Market Performance (Sales, Revenue)
4.2 Key Players in North America
5 Europe ONCOLOGY DRUGS Market Assessment by Type
4.1 Europe Market Performance (Sales, Revenue)
4.2 Key Players in Europe
6 South America ONCOLOGY DRUGS Market Assessment by Type
4.1 South America Market Performance (Sales, Revenue)
4.2 Key Players in South America
7 Middle Easr and Africa ONCOLOGY DRUGS Market Assessment by Type
4.1 Middle Easr and Africa Market Performance (Sales, Revenue)
4.2 Key Players in Middle Easr and Africa
8 World ONCOLOGY DRUGS Market Assessment by Type
8.1 Asia Pacific ONCOLOGY DRUGS Market Assessment by Application (Consumption and Market Share)
8.2 North America ONCOLOGY DRUGS Market Assessment by Application (Consumption and Market Share)
8.3 Europe ONCOLOGY DRUGS Market Assessment by Application (Consumption and Market Share)
8.4 South America ONCOLOGY DRUGS Market Assessment by Application (Consumption and Market Share)
8.5 Middle East and Africa ONCOLOGY DRUGS Market Assessment by Application (Consumption and Market Share)
9 Company Profiles/Analysis
9.1 Novartis A.G
9.1.1 Novartis A.G Profiles
9.1.2 Novartis A.G Product Portfolio
9.1.3 Novartis A.G ONCOLOGY DRUGS Business Performance
9.1.4 Novartis A.G ONCOLOGY DRUGS Business Development and Market Status
9.2 Laboratrio Cristlia
9.2.1 Laboratrio Cristlia Profiles
9.2.2 Laboratrio Cristlia Product Portfolio
9.2.3 Laboratrio Cristlia ONCOLOGY DRUGS Business Performance
9.2.4 Laboratrio Cristlia ONCOLOGY DRUGS Business Development and Market Status
9.3 Medley Genomics
9.3.1 Medley Genomics Profiles
9.3.2 Medley Genomics Product Portfolio
9.3.3 Medley Genomics ONCOLOGY DRUGS Business Performance
9.3.4 Medley Genomics ONCOLOGY DRUGS Business Development and Market Status
9.4 F. Hoffmann-La Roche Ltd
9.4.1 F. Hoffmann-La Roche Ltd Profiles
9.4.2 F. Hoffmann-La Roche Ltd Product Portfolio
9.4.3 F. Hoffmann-La Roche Ltd ONCOLOGY DRUGS Business Performance
9.4.4 F. Hoffmann-La Roche Ltd ONCOLOGY DRUGS Business Development and Market Status
9.5 Icon Plc.
9.5.1 Icon Plc. Profiles
9.5.2 Icon Plc. Product Portfolio
9.5.3 Icon Plc. ONCOLOGY DRUGS Business Performance
9.5.4 Icon Plc. ONCOLOGY DRUGS Business Development and Market Status
9.6 Sanofi S.A.
9.6.1 Sanofi S.A. Profiles
9.6.2 Sanofi S.A. Product Portfolio
9.6.3 Sanofi S.A. ONCOLOGY DRUGS Business Performance
9.6.4 Sanofi S.A. ONCOLOGY DRUGS Business Development and Market Status
9.7 Laboratoires Pierre Fabre
9.7.1 Laboratoires Pierre Fabre Profiles
9.7.2 Laboratoires Pierre Fabre Product Portfolio
9.7.3 Laboratoires Pierre Fabre ONCOLOGY DRUGS Business Performance
9.7.4 Laboratoires Pierre Fabre ONCOLOGY DRUGS Business Development and Market Status
9.8 Eurofarma Laboratrios S.A.
9.8.1 Eurofarma Laboratrios S.A. Profiles
9.8.2 Eurofarma Laboratrios S.A. Product Portfolio
9.8.3 Eurofarma Laboratrios S.A. ONCOLOGY DRUGS Business Performance
9.8.4 Eurofarma Laboratrios S.A. ONCOLOGY DRUGS Business Development and Market Status
9.9 Ach Laboratrios Farmacuticos S.A.
9.9.1 Ach Laboratrios Farmacuticos S.A. Profiles
9.9.2 Ach Laboratrios Farmacuticos S.A. Product Portfolio
9.9.3 Ach Laboratrios Farmacuticos S.A. ONCOLOGY DRUGS Business Performance
9.9.4 Ach Laboratrios Farmacuticos S.A. ONCOLOGY DRUGS Business Development and Market Status
9.10 Laboratorios IMA
9.10.1 Laboratorios IMA Profiles
9.10.2 Laboratorios IMA Product Portfolio
9.10.3 Laboratorios IMA ONCOLOGY DRUGS Business Performance
9.10.4 Laboratorios IMA ONCOLOGY DRUGS Business Development and Market Status
10 World ONCOLOGY DRUGS Market Assessment by Players
10.1 Global ONCOLOGY DRUGS Sales (K Units) and Market Share by Players 2014-2020
10.2 Global ONCOLOGY DRUGS Revenue (M USD) and Market Share by Players 2014-2020
10.3 Global ONCOLOGY DRUGS Price (USD/Unit) of Players 2014-2020
10.4 Global ONCOLOGY DRUGS Gross Margin of Players 2014-2020
10.5 Market Concentration
11 Regional Market Performance by Segment of Players
11.1 North America
11.1.1 North America ONCOLOGY DRUGS Sales Assessment of Players 2014-2020
11.1.2 North America ONCOLOGY DRUGS Revenue Assessment of Players 2014-2020
11.1.3 North America ONCOLOGY DRUGS Price Assessment of Players 2014-2020
11.1.4 North America ONCOLOGY DRUGS Gross Margin Assessment of Players 2014-2020
11.1.5 Market Concentration
11.2 Europe
11.2.1 Europe ONCOLOGY DRUGS Sales Assessment of Players 2014-2020
11.2.2 Europe ONCOLOGY DRUGS Revenue Assessment of Players of Manufacturers 2014-2020
11.2.3 Europe ONCOLOGY DRUGS Price Assessment of Players 2014-2020
11.2.4 Europe ONCOLOGY DRUGS Gross Margin Assessment of Players 2014-2020
11.2.5 Market Concentration
11.3 Asia-Pacific Market Performance for Manufacturers
11.3.1 Asia-Pacific ONCOLOGY DRUGS Sales Assessment of Players 2014-2020
11.3.2 Asia-Pacific ONCOLOGY DRUGS Revenue Assessment of Players 2014-2020
11.3.3 Asia-Pacific ONCOLOGY DRUGS Price Assessment of Players 2014-2020
11.3.4 Asia-Pacific ONCOLOGY DRUGS Gross Margin Assessment of Players 2014-2020
11.3.5 Market Concentration
11.4 South America Market Performance for Players
11.4.1 South America ONCOLOGY DRUGS Sales Assessment of Players 2014-2020
11.4.2 South America ONCOLOGY DRUGS Revenue Assessment of Players 2014-2020
11.4.3 South America ONCOLOGY DRUGS Price Assessment of Players 2014-2020
11.4.4 South America ONCOLOGY DRUGS Gross Margin Assessment of Players 2014-2020
11.4.5 Market Concentration
11.5 Middle East and Africa Market Performance for Players
11.5.1 Middle East and Africa ONCOLOGY DRUGS Sales Assessment of Players 2014-2020
11.5.2 Middle East and Africa ONCOLOGY DRUGS Revenue Assessment of Players 2014-2020
11.5.3 Middle East and Africa ONCOLOGY DRUGS Price Assessment of Players 2014-2020
11.5.4 Middle East and Africa ONCOLOGY DRUGS Gross Margin Assessment of Players 2014-2020
11.5.5 Market Concentration
12 Regional Market Performance by Segment of Countries
12.1 Asia Pacific
12.1.1 Asia Pacific ONCOLOGY DRUGS Sales by Countries/Regions 2014-2020
12.1.2 Asia Pacific ONCOLOGY DRUGS Revenue by Countries/Regions 2014-2020
12.1.3 Asia Pacific ONCOLOGY DRUGS Average Price by Countries/Regions 2014-2020
12.2 North America
12.2.1 North America ONCOLOGY DRUGS Sales by Countries/Regions 2014-2020
12.2.2 North America ONCOLOGY DRUGS Revenue by Countries/Regions 2014-2020
12.2.3 North America ONCOLOGY DRUGS Average Price by Countries/Regions 2014-2020
12.3 Europe
12.3.1 Europe ONCOLOGY DRUGS Sales by Countries/Regions 2014-2020
12.3.2 Europe ONCOLOGY DRUGS Revenue by Countries/Regions 2014-2020
12.3.3 Europe ONCOLOGY DRUGS Average Price by Countries/Regions 2014-2020
12.4 South America
12.4.1 South America ONCOLOGY DRUGS Sales by Countries/Regions 2014-2020
12.4.2 South America ONCOLOGY DRUGS Revenue by Countries/Regions 2014-2020
12.4.3 South America ONCOLOGY DRUGS Average Price by Countries/Regions 2014-2020
12.5 Middle East and Africa
12.5.1 Middle East and Africa ONCOLOGY DRUGS Sales by Countries/Regions 2014-2020
12.5.2 Middle East and Africa ONCOLOGY DRUGS Revenue by Countries/Regions 2014-2020
12.5.3 Middle East and Africa ONCOLOGY DRUGS Average Price by Countries/Regions 2014-2020
13 Technology and Opportunity
13.1 Technology
13.2 Market Opportunity
14 World ONCOLOGY DRUGS Sales & Revenue Forecast 2021-2026
14.1 World ONCOLOGY DRUGS Sales and Revenue Forecast by Regions 2021-2026
14.1.1 World ONCOLOGY DRUGSSales and Market Share by Regions
14.1.2 World ONCOLOGY DRUGSRevenue and Market Share by Regions
15 Asia ONCOLOGY DRUGS Market Forecast 2021-2026
15.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
15.1.1 Oral Therapy
15.1.2 Injectable Therapy
15.2 Consumption Forecast by Application, 2021-2026
16 North America ONCOLOGY DRUGS Market Forecast 2021-2026
16.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
16.1.1 Oral Therapy
16.1.2 Injectable Therapy
16.2 Consumption Forecast by Application, 2021-2026
17 Europe ONCOLOGY DRUGS Market Forecast 2021-2026
17.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
17.1.1 Oral Therapy
17.1.2 Injectable Therapy
17.2 Consumption Forecast by Application, 2021-2026
18 South America ONCOLOGY DRUGS Market Forecast 2021-2026
18.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
18.1.1 Oral Therapy
18.1.2 Injectable Therapy
18.2 Consumption Forecast by Application, 2021-2026
19 Middle East and Africa ONCOLOGY DRUGS Market Forecast 2021-2026
19.1 Sales and Revenue (M USD) Forecast by Type, 2021-2026
19.1.1 Oral Therapy
19.1.2 Injectable Therapy
19.2 Consumption Forecast by Application, 2021-2026
20 Price (USD/Unit) and Gross Profit Forecast
20.1 Global ONCOLOGY DRUGS Price (USD/Unit) Trend 2021-2026
20.2 Global ONCOLOGY DRUGS Gross Profit Trend 2021-2026
21 Conclusion